Bernstein maintains Outperform on Zydus Life after Novartis exits its ALS drug, improving the commercial landscape for Usnoflast ahead of key clinical data.
Market Samachar is a news aggregator. This article was originally published by NDTV Profit - Latest. Tap the button above to read the full story on their site.